Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections

N/ANot Yet RecruitingNCT06890455

Sohag University120 enrolled

Overview

Calprotectin extracted from stool can be detected easily using ELISA. Numerous studies have shown that fecal calprotectin concentrations demonstrate a good correlation with intestinal inflammation This study aims to detect the relationship between fecal calprotectin and Blastocystis hominis and Entamoeba histolytica infections.

Study Type

OBSERVATIONAL

Enrollment

120

Conditions

Fecal Calprotectin in Intestinal Protozoa

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 120 fecal samples will be collected as the following: * 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica. * 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection. * 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites). Exclusion Criteria: * persons received antiparasitic drugs or antibiotic 2 weeks before sample collection Patients with mixed intestinal protozoa Patients with intestinal protozoa rather than Entamoeba histolytica and Blastocystis

Locations (1)

Sohag University

Sohag, Egypt

Outcomes

Primary Outcomes

Prevalence of Blastocystis and Entamoeba

Time frame: 2 months

Secondary Outcomes

Number of persons have high fecal calprotectin

Time frame: 6 months

Central Contacts

Youstina Kamel Boles, Demonstrator

CONTACT

+20 12 73435308 youstena.kamel@med.sohag.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.